Navigation Links
Concerto HealthAI to Present at J.P. Morgan’s 37th Annual Healthcare Conference
Date:1/7/2019

Concerto HealthAI, a technology leader in definitive Real World Data (RWD) and Artificial Intelligence solutions for precision health in oncology and other key therapeutic areas, and its Chief Executive Officer, Dr. Jeff Elton, will present at J.P Morgan’s exclusive meeting of investors, entrepreneurs and executives spanning the entire healthcare landscape, on January 8, 2019, at 2:30 p.m. in San Francisco, CA.

Concerto HealthAI is the emerging leader in integrated clinical RWD, AI solutions and outcomes science and has the largest and fastest-growing RWD oncology dataset in the market. Concerto HealthAI has an exclusive 10-year partnership with CancerLinQ, a non-profit subsidiary of the American Society of Clinical Oncology (ASCO). With CancerLinQ, Concerto HealthAI is bringing its clinical and technical expertise to collaborative research efforts with the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) to accelerate insights and understanding of the real-world use, tolerability, and effectiveness of immune checkpoint inhibitors.

Combined with its AI platform, eurekaHealth™, Concerto HealthAI’s data and analytics solutions support and streamline drug development, clinical trials, HEOR analytics, and improve patient outcomes. Concerto HealthAI is a leader in clinical outcomes research, HEOR, prospective real-world digital registries and clinical development synthetic control arm studies – the forefront of Real-World Evidence solutions.

“At Concerto HealthAI, we are combining technology with RWD at a scale that has been unavailable to most healthcare organizations until now,” said Dr. Elton, the CEO of Concerto HealthAI. “This means a comprehensive – and accelerated – approach to generating insights, designing studies and finding patterns for precision medicine and improved patient outcomes that just isn’t possible in current clinical or scientific literature or practice.”

One such application of the eurekaHealth AI platform, presented at ASCO 2018, focused on side effects of chemotherapy in breast cancer patients. One in five breast cancer patients receiving chemo are susceptible to a life-threatening side-effect called neutropenia, where the immune system loses its ability to fight off infections. Leveraging eurekaHealth on a de-identified real-world dataset of 10,288 breast cancer patients, Concerto HealthAI’s platform demonstrated an average 27% increase in prediction of chemo-induced neutropenia compared to existing studies.

In September, Concerto HealthAI strengthened its leadership team with the appointment of Jeff Elton, Ph.D., as CEO. Dr. Elton brings over 25 years of experience in healthcare and life sciences and previously was Managing Director, Accenture Strategy & Predictive Health Intelligence, global COO of Novartis’ Institutes for BioMedical Research and a McKinsey partner in Pharmaceuticals & Medical Products. He is a founding board member and senior advisor to several early-stage biotechnology and AI companies and a member of the Massachusetts Biotechnology Council and Forbes Technology Council. Dr. Elton co-authored the groundbreaking book, “Healthcare Disrupted: Next Generation Business Models and Strategies.” Published in 2016, “Healthcare Disrupted” created an industry roadmap for AI, advanced analytics, real-world data and digital medical solutions.

Concerto HealthAI is a portfolio company of SymphonyAI, a group of companies that provide leading AI-centric solutions for transforming the business enterprise for the retail, CPG, healthcare and industrial verticals. Founded by Dr. Romesh Wadhwani and backed with his $1 billion investment, SymphonyAI is one of the fastest growing companies in the business-to-business AI solutions sector with 1,500 employees.

“We are on the verge of a new age in healthcare and I’m thrilled to join Concerto HealthAI and guide this transformation that will greatly improve patient treatments and outcomes through the use of RWD and AI,” Dr. Elton said.

About Concerto HealthAI
Concerto HealthAI is a technology leader in definitive Real-world Data (RWD) and AI solutions for precision oncology. Our mission is to accelerate improvements in clinical outcomes for cancer patients through our partnerships, unique real-world data assets, leading AI-based technologies, and the world’s top outcomes research and data science talent. For more information, visit us at http://www.concertohealthai.com. Concerto HealthAI is a SymphonyAI company. eurekaHealth is a trademark of Concerto HealthAI.

Read the full story at https://www.prweb.com/releases/concerto_healthai_to_present_at_j_p_morgans_37th_annual_healthcare_conference/prweb16016405.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Governor Corbett Presented 2013 Biotechnology Industry Organization Governor of the Year Award
2. Underrepresented minority students receive fellowships in digestive disease and nutrition research
3. UCLA life scientists present new insights on climate change and species interactions
4. Efficacy of acupressure to relieve migraine nausea presented at International Headache Congress
5. Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients
6. Yin-yang effect of sodium and chloride presents salt conundrum
7. Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma
8. New research on potential avocado health benefits presented at International Congress of Nutrition
9. Array BioPharma to Present at the NewsMakers in the Biotech Industry Conference
10. Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference
11. Pest control presentations at Entomology 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2019)... ... May 30, 2019 , ... Researchers from Ambry Genetics ... significant differences in the prevalence of hereditary genetic mutations, also called germline mutations, ... women. Results will be presented at the 2019 American Society of Clinical Oncology ...
(Date:5/24/2019)... ... , ... The newest edition of Crystallography Times from Rigaku ... , Crystallography Times is a monthly electronic newsletter published by Rigaku Oxford Diffraction ( ... by presenting the latest news and crystallographic research. , “Crystallography in the News” ...
(Date:5/21/2019)... ... May 21, 2019 , ... If a ... know? How can we tell it apart from the millions of microorganisms that ... multi-institution research team, including Eric Young , assistant professor of chemical engineering ...
Breaking Biology News(10 mins):
(Date:6/11/2019)... ... 2019 , ... Veterinary Regenerative Medicine company, VetStem Biopharma ... that their GMP facility for cell production is now approved by the California ... an important milestone for VetStem as it expands into contract cell manufacturing services. ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... the USPTO providing proprietary interest to our methodology, processes, and diagnostic techniques. ... AND TREATMENT… extends Somnology’s IP rights including our proprietary sleep scoring methodology. ...
(Date:5/22/2019)... (PRWEB) , ... May 22, 2019 , ... Artemis ... closed a $8 million Series A funding round co-led by Astanor Ventures ... Empire State Development Fund and iSelect Fund . The company has raised ...
(Date:5/14/2019)... ... May 13, 2019 , ... Leak Detection Associates (LDA), the ... Biotechnology, Medical Device and Food Packaging Industries’ is excited to announce the go-live ... LDA’s ability to communicate directly with the marketplace; serving as a destination to ...
Breaking Biology Technology: